{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Lennol MP"],"funding":["Consejo Superior de Investigaciones Científicas","Instituto de Salud Carlos III","Agencia Estatal de Investigación","Ministerio de Ciencia e Innovación","Ministerio de Economía y Competitividad","Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas","Conselleria d'Educació, Investigació, Cultura i Esport"],"pubmed_abstract":["Various species of the SARS-CoV-2 host cell receptor, the angiotensin-converting enzyme 2 (ACE2), are present in serum, which may result from virus entry and subsequent proteolytic processing of the membrane receptor. We have recently demonstrated changes of particular ACE2 species in virus infected humans, either cleaved fragments or circulating full-length species. Here, we further explore the potential of serum ACE2 as a biomarker to test SARS-CoV-2 infection and vaccine efficacy in virus susceptible transgenic K18-hACE2 mice expressing human ACE2. First, in serum samples derived from K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2, we observed an increase in the levels of cleaved ACE2 fragment at day 2 post-challenge, which may represent the subsequent proteolytic processing"],"journal":["Frontiers in immunology"],"pagination":["1001951"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9597869"],"repository":["biostudies-literature"],"pubmed_title":["Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy."],"pmcid":["PMC9597869"],"pubmed_authors":["Esteban M","Lennol MP","Garcia-Ayllon MS","Saez-Valero J","Garcia-Arriaza J"],"additional_accession":[]},"is_claimable":false,"name":"Serum angiotensin-converting enzyme 2 as a potential biomarker for SARS-CoV-2 infection and vaccine efficacy.","description":"Various species of the SARS-CoV-2 host cell receptor, the angiotensin-converting enzyme 2 (ACE2), are present in serum, which may result from virus entry and subsequent proteolytic processing of the membrane receptor. We have recently demonstrated changes of particular ACE2 species in virus infected humans, either cleaved fragments or circulating full-length species. Here, we further explore the potential of serum ACE2 as a biomarker to test SARS-CoV-2 infection and vaccine efficacy in virus susceptible transgenic K18-hACE2 mice expressing human ACE2. First, in serum samples derived from K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2, we observed an increase in the levels of cleaved ACE2 fragment at day 2 post-challenge, which may represent the subsequent proteolytic processing","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-18T20:33:24.126Z","creation":"2025-02-19T00:31:36.008Z"},"accession":"S-EPMC9597869","cross_references":{"pubmed":["36311758"],"doi":["10.3389/fimmu.2022.1001951"]}}